Milani Valeria, Noessner Elfriede
Clinical Cooperation Group on Hyperthermia, Internal Medicine Department III, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377, Munich, Germany.
Cancer Immunol Immunother. 2006 Mar;55(3):312-9. doi: 10.1007/s00262-005-0052-3. Epub 2005 Sep 3.
The primary rationale for the application of clinical hyperthermia in the therapy of cancer is based on the direct cytotoxic effect of heat and the radio-chemosensitization of tumor cells. More recently, additional attention is given to the observation that heat and heat-shock proteins can activate the host's immune system. The expression of heat-shock genes and proteins provides an adaptive mechanism for stress tolerance, allowing cells to survive non-physiologic conditions. However, the same adaptive mechanism can ultimately favor malignant transformation by interfering with pathways that regulate cell growth and apoptosis. Cytoprotection and thermotolerance raised the concern that heat-treated tumor cells might also be resistant to attack by immune effector mechanisms. Many studies, including those from our group, address this concern and document that heat-exposure, although transiently modulating sensitivity to CTL, do not hinder CTL attack. Moreover, there are promising reports of heat-related upregulation of NK-activating ligands, rendering those tumors which have lost MHC class I molecules target for NK cell attack. Heat-induced cytoprotection, therefore, does not necessarily extend protection from cytotoxic immune mechanisms. When interpreting the effects of heat, it is important to keep in mind that thermal effects on cell physiology are strongly dependent on the thermal dose, which is a function of the magnitude of change in temperature and the duration of heat exposure. The thermal dose required to induce cell death in vitro strongly varies from cell type to cell type and depends on microenvironmental factors (Dewey 1994). Therefore, to dissect the immunological behaviour of a given tumor and its micro-environment at different thermal doses, it is essential to characterize the thermosensitivity of every single tumor type and assess the proportion of cells surviving a given heat treatment. In this review, we summarize the pleiotropic effects that heat exposure has on tumor cells. In particular, we focus on the effects of heat on the antigen presentation of tumor cells and their susceptibility to immune effector mechanisms. We emphasize that the response to thermal stress is not a one-time point event, but rather a time period starting with the heat exposure and extending over several days of recovery. In addition, the response of tumor cells and their susceptibility to immune effector cells is strongly dependent on the model system, on the magnitude and duration of the thermal stress and on the time of recovery after heat exposure. Consideration of these aspects might help to explain some of the conflicting results that are reported in the field of thermal stress response.
临床热疗应用于癌症治疗的主要理论依据是基于热的直接细胞毒性作用以及肿瘤细胞的放射化学增敏作用。最近,人们更多地关注到热和热休克蛋白能够激活宿主免疫系统这一现象。热休克基因和蛋白的表达提供了一种应激耐受的适应性机制,使细胞能够在非生理条件下存活。然而,同样的适应性机制最终可能通过干扰调节细胞生长和凋亡的途径而有利于恶性转化。细胞保护和热耐受引发了人们的担忧,即热处理后的肿瘤细胞可能也会对免疫效应机制的攻击产生抗性。许多研究,包括我们小组的研究,都探讨了这一问题,并证明热暴露虽然会短暂调节对细胞毒性T淋巴细胞(CTL)的敏感性,但并不妨碍CTL的攻击。此外,有一些关于热相关的自然杀伤细胞(NK)激活配体上调的报道,这使得那些失去主要组织相容性复合体(MHC)I类分子的肿瘤成为NK细胞攻击的目标。因此,热诱导的细胞保护不一定能扩展到对细胞毒性免疫机制的保护。在解释热的作用时,重要的是要记住,热对细胞生理的影响强烈依赖于热剂量,热剂量是温度变化幅度和热暴露持续时间的函数。在体外诱导细胞死亡所需的热剂量因细胞类型而异,并且取决于微环境因素(杜威,1994年)。因此,为了剖析给定肿瘤及其微环境在不同热剂量下的免疫行为,必须表征每种肿瘤类型的热敏感性,并评估在给定热处理后存活的细胞比例。在这篇综述中,我们总结了热暴露对肿瘤细胞的多效性影响。特别是,我们关注热对肿瘤细胞抗原呈递及其对免疫效应机制敏感性的影响。我们强调,对热应激的反应不是一次性事件,而是一个从热暴露开始并持续数天恢复的时间段。此外,肿瘤细胞的反应及其对免疫效应细胞的敏感性强烈依赖于模型系统、热应激的幅度和持续时间以及热暴露后的恢复时间。考虑这些方面可能有助于解释热应激反应领域中报道的一些相互矛盾的结果。